EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 12 (Décembre 2023) Med Sci (Paris), 39 12 (2023) 917-920 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 39, Numéro 12, Décembre 2023
Page(s) 917 - 920
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2023171
Publié en ligne 18 décembre 2023
  1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016 ; 374 : 2209–2221. [Google Scholar]
  2. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 : 1345–77. [CrossRef] [PubMed] [Google Scholar]
  3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020; 383 : 617–29. [CrossRef] [PubMed] [Google Scholar]
  4. Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk. Lymphoma 2018 ; 59 : 2273–2286. [CrossRef] [PubMed] [Google Scholar]
  5. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017 ; 377 : 454–464. [CrossRef] [PubMed] [Google Scholar]
  6. Erba HP, Montesinos P, Kim H-J, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 : 1571–83. [CrossRef] [PubMed] [Google Scholar]
  7. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019 ; 381 : 1728–1740. [CrossRef] [PubMed] [Google Scholar]
  8. McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov 2019 ; 9 : 1050–1063. [CrossRef] [PubMed] [Google Scholar]
  9. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov 2021; 2 : 125–34. [CrossRef] [PubMed] [Google Scholar]
  10. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer 2021; 21 : 669–80. [CrossRef] [PubMed] [Google Scholar]
  11. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov 2022; 12 : 31–46. [CrossRef] [PubMed] [Google Scholar]
  12. Ju H-Q, Zhan G, Huang A, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia 2017 ; 31 : 2143–2150. [CrossRef] [PubMed] [Google Scholar]
  13. Gallipoli P, Giotopoulos G, Tzelepis K, et al. Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood 2018 ; 131 : 1639–1653. [CrossRef] [PubMed] [Google Scholar]
  14. Bjelosevic S, Gruber E, Newbold A, et al. Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukemia. Cancer Discov 2021; 11 : 1582–99. [CrossRef] [PubMed] [Google Scholar]
  15. Birsen R, Grignano E, Chapuis N, et al. Ferroptose et cancer : implications physiopathologiques et thérapeutiques. Med Sci (Paris) 2021; 37 : 726–34. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  16. Sen U, Coleman C, Sen T. Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer 2023; 9 : 480–9. [CrossRef] [PubMed] [Google Scholar]
  17. Sabatier M, Birsen R, Lauture L, et al. C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. Cancer Discov 2023; 13 : 1720–47. [CrossRef] [PubMed] [Google Scholar]
  18. Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun 2019 ; 10 : 1617. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.